1
|
Priebe S, Bröker M. Initial response to active drug and placebo predicts outcome of antidepressant treatment. Eur Psychiatry 2020; 12:28-33. [DOI: 10.1016/s0924-9338(97)86376-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/1995] [Accepted: 09/24/1996] [Indexed: 10/18/2022] Open
Abstract
SummaryIn this study we tested whether initial clinical change (ICC) and initial subjective response (ISR) predict the outcome of antidepressant pharmacotherapy and whether ICC and ISR as predictors reflect specific pharmacological actions or a placebo effect. Forty patients with major depression were treated with three different antidepressants for 4 weeks. Overall clinical change and final subjective response were taken as outcome criteria. The patients were randomly assigned to two subgroups in a double-blind design. Initially, one group received the active drug and the other placebo. Afterwards, all patients were given the active drug. Significant correlations were found between ICC and ISR and at least one of the outcome criteria in the total sample and in each subgroup. The findings show that ICC and ISR may be significant predictors of outcome. The predictive value of ICC and ISR is not due to initial pharmacological effects, but to non-specific treatment factors.
Collapse
|
2
|
Rationale for BPRS use in routine clinical practice: quantitative assessment of psychopathology, consistent with clinical sense. Eur Psychiatry 2020. [DOI: 10.1017/s0924933800003898] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
SummaryThe Brief Psychiatric Rating Scale (BPRS) is expected to provide a valuable instrument for routine evaluation of the patient's status and correct interpretation of concentrations measured during therapeutic monitoring of antipsychotic drugs. Inpatient files were searched for information relative to acute episodes and BPRS items were scored every 10 days until discharge from the hospital according to a retrospective scheme. Eighty patients were included, who met DSM III criteria for schizophrenia and bipolar disorder. Clusters of symptoms that tend to appear together were identified through principal components analysis and are in keeping with factors described previously. Differences with respect to diagnosis further suggest that such clusters convey clinically relevant information. The time course of haloperidol action was also investigated: an average 51 % improvement was observed over the first 10 days, while the proportion of patients showing a 50% or larger BPRS decrease at the time of discharge reached 90%. The prominent contribution of changes in positive, florid symptoms to global improvement is also described. Finally, association of clinical improvement with a shorter period of hospitalization is shown. These results indicate that the BPRS represents a level of abstraction compatible with the way clinicians communicate and that its introduction into routine practice may allow for better description of the course of illness
Collapse
|
3
|
Stephan KE, Siemerkus J, Bischof M, Haker H. Hat Computational Psychiatry Relevanz für die klinische Praxis der Psychiatrie? ACTA ACUST UNITED AC 2017. [DOI: 10.1024/1661-4747/a000296] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Zusammenfassung. Computational Psychiatry (CP) ist ein junges Wissenschaftsfeld an der Schnittstelle zwischen der klinischen Psychiatrie und den mathematischen Neurowissenschaften, das sich in den letzten Jahren zu entfalten begonnen hat. Dieser Artikel widmet sich den möglichen klinischen Implikationen dieser jungen Disziplin. Wir (i) beginnen mit einer kurzen Übersicht über die Geschichte, Ziele und Inhalte der CP, (ii) beschreiben die zentralen Themen, Modelle und Theorien der CP, (iii) untersuchen die Relevanz und das Potenzial modell-basierter diagnostischer Tests (computational assays) für die Lösung zentraler Probleme in der klinischen Psychiatrie, und (iv) stellen zukünftige Herausforderungen und Chancen der CP dar.
Collapse
Affiliation(s)
- Klaas Enno Stephan
- Translational Neuromodeling Unit (TNU), Institut für Biomedizinische Technik, Universität Zürich & ETH Zürich, Schweiz
| | - Jakob Siemerkus
- Translational Neuromodeling Unit (TNU), Institut für Biomedizinische Technik, Universität Zürich & ETH Zürich, Schweiz
- Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Psychiatrische Universitätsklinik Zürich, Schweiz
| | - Martin Bischof
- Translational Neuromodeling Unit (TNU), Institut für Biomedizinische Technik, Universität Zürich & ETH Zürich, Schweiz
- Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Psychiatrische Universitätsklinik Zürich, Schweiz
| | - Helene Haker
- Translational Neuromodeling Unit (TNU), Institut für Biomedizinische Technik, Universität Zürich & ETH Zürich, Schweiz
| |
Collapse
|
4
|
Leucht S, Zhao J. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program. J Psychopharmacol 2014; 28:387-94. [PMID: 24429222 DOI: 10.1177/0269881113517956] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVE The purpose of this study was to assess whether early symptom improvement predicts later treatment outcome in patients with schizophrenia. METHODS Data were pooled from intent-to-treat (ITT) populations of three six-week randomized controlled studies with fixed doses of asenapine (ASE; n=470), olanzapine (OLA; n=95), risperidone (RIS; n=56), haloperidol (HAL; n=112), or placebo (PLA; n=275). Early improvement was defined as a 20% reduction of Positive and Negative Syndrome Scale (PANSS) total score at week 2, compared to baseline (primary criterion). Treatment outcome at week 6 was defined as response (PANSS: ≥50% score reduction) or remission (PANSS item score ≤3 on selected items at week 6). Odds ratios (ORs) and predictive performance statistics were calculated. RESULTS Statistically significant associations between early improvement (at week 2) and treatment outcome (at week 6) were observed for all treatment groups except OLA; as evidenced by increased ORs for response. Analysis of associations between early improvement and remission, as defined by Andreasen et al. (2005), revealed a statistically significant relationship for ASE and PLA-treated patients only. Predictive performance statistics revealed higher negative predictive value (NPV) and sensitivity rates, and comparably lower positive predictive value (PPV) and specificity rates across treatment groups for both response and remission. CONCLUSION It is suggested that absence of improvement within two weeks of treatment may predict the unlikely success of subsequent pharmacological intervention.
Collapse
Affiliation(s)
- Stefan Leucht
- 1Department of Psychiatry and Psychotherapy, Technische Universität München, München, Germany
| | | |
Collapse
|
5
|
Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use. Prog Neuropsychopharmacol Biol Psychiatry 2014; 48:207-12. [PMID: 24096139 DOI: 10.1016/j.pnpbp.2013.09.015] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2013] [Revised: 09/18/2013] [Accepted: 09/25/2013] [Indexed: 11/21/2022]
Abstract
The Paliperidone ER Treatment in Acute Intervention (PERTAIN) study was designed to explore treatment response, tolerability, and safety of flexible doses of paliperidone ER in patients with schizophrenia admitted for an acute exacerbation. This paper addresses a secondary analysis of PERTAIN data designed to explore predictors for treatment response, flexible dosing, and concomitant benzodiazepine use. This prospective, multicenter, phase 3b, open-label, single-arm, 6-week study used flexible doses of paliperidone ER (3 to 12mg once daily) to treat patients hospitalized for an acute exacerbation of schizophrenia, reflecting more closely daily clinical practice. Predictive models were evaluated for paliperidone ER flexible dosing, treatment response, and concomitant treatment with benzodiazepines as distinct independent variables. For the analysis of explanatory variables, a stepwise logistic regression was used, taking into account patient age, gender, body mass index, diagnosis and duration of schizophrenia, number of prior hospitalizations, psychotic symptoms (PANSS), disease severity (CGI-S), and patient functioning (PSP) at baseline. Early response (defined as response within 2weeks of treatment initiation) was also used as a predictor. Clinical response (defined as ≥30% decrease in PANSS total score and ≥1 point decrease in CGI-S from baseline to endpoint) was predicted by early clinical response (p<0.001) and there was a trend for the diagnosis of paranoid schizophrenia vs. other types of schizophrenia to predict clinical response (p=0.0525). High response (defined as ≥50% decrease in PANSS total score and ≥2 points decrease in CGI-S from baseline to endpoint) was predicted by early high response, higher baseline CGI-S, or female gender. More severely ill patients with a higher baseline CGI-S were twice likely to be treated concomitantly with a benzodiazepine.
Collapse
|
6
|
Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. DIALOGUES IN CLINICAL NEUROSCIENCE 2011. [PMID: 21842613 PMCID: PMC3182000 DOI: 10.31887/dcns.2011.13.2/ccorrell] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
State-of-the art clinical trial design and methodology are enormously important for the advancement of the field. In contrast, the critical relevance of trial conduct and implementation have only more recently been the focus of discussion and research. Although randomized controlled trials are generally considered the gold standard for the assessment of pharmacologic and nonpharmacologic interventions in medicine, trials are vulnerable to complications and influences that can seriously compromise their success, Like interventions, trial design and conduct are also contextual. They need to be individualized and adapted to a number of relevant variables, such as setting, population, illness phase, interventions, patient and rater expectations and biases, and the overall aims of the investigation. While this means that there is no unified approach possible, certain general principles and guidelines require careful consideration. Knowledge of basic solutions and alternatives, and the recognition of the complex challenges that need to be addressed proactively can help to minimize unwanted outcomes, including trial failure and uninformative or falsely negative outcomes. Moreover, novel design alternatives need to be explored that target sample enrichment according to the study question and enhancement of precision in the measurement of relevant outcomes. We propose two novel design strategies that take advantage of the recently validated early antipsychotic response paradigm (that has also been observed with antidepressants and mood stabilizers). In the “early responder randomized discontinuation design” all patients are assigned to the active drug, and only those who had at least a minimal response at 2 weeks are enrolled in a double-blind, placebo-controlled discontinuation trial, enriching the placebo controlled trial portion with true drug responders. In the mirror image “early nonresponder randomized dose increase or augmentation design,” early nonresponders at 2 weeks are assigned to staying on the medication or going either to a higher dose or an augmentation agent. It is hoped that through increased attention to the issues raised in this article and further refinement of trial methodology and conduct, the field will make much needed additional progress in the prevention and treatment of schizophrenia.
Collapse
Affiliation(s)
- Christoph U Correll
- The Zucker Hillside Hospital, Psychiatry Research, North Shore - Long Island Jewish Health System, Glen Oaks, New York 11004, USA.
| | | | | |
Collapse
|
7
|
Abstract
Despite pharmacologic advances, the treatment of schizophrenia remains a challenge, and suboptimal outcomes are still all too frequent. Although treatment goals of response, remission, and recovery have been defined more uniformly, a good “effectiveness” measure mapping onto functional outcomes is still lacking. Moreover, the field has to advance in transferring measurement-based approaches from research to clinical practice. There is an ongoing debate whether, and which, first- or second-generation antipsychotics should be used. However, an individualized treatment approach needs to consider current symptoms, comorbid conditions, past therapeutic response, and adverse effects, as well as patient choice and expectations. Moreover, acute and long-term goals and effects of medication treatment need to be balanced. While the acute response to appropriately dosed first-generation antipsychotics may not differ much from second-generation antipsychotics, advantages of lower rates of extrapyramidal side effects, tardive dyskinesia, and, possibly, relapse may favor second-generation antipsychotics. However, when considering individual adverse effect prof iles, the differentiation into first- and second-generation antipsychotics as unified classes can not be upheld, and a more differentiated view and treatment selection is required. To date, clozapine is the only evidence-based treatment for refractory patients, and the role of antipsychotic polypharmacy and other augmentation strategies remains unclear, at best. To improve the treatment outcomes in schizophrenia, research efforts are needed that elucidate biomarkers of the illness and of treatment response (both therapeutic and adverse effects). Moreover, new treatment options are needed that affect nondopaminergic targets with relevance for symptom reduction, relapse prevention, enhanced efficacy for nonresponders, and reduced key adverse effects.
Collapse
Affiliation(s)
- John M Kane
- Zucker Hillside Hospital, 75-59 263rd Street, Glen Oaks, NY 11004, USA.
| | | |
Collapse
|
8
|
Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010; 71:1115-24. [PMID: 20923620 PMCID: PMC3065240 DOI: 10.4088/jcp.10r06264yel] [Citation(s) in RCA: 161] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2010] [Accepted: 07/09/2010] [Indexed: 10/19/2022]
Abstract
Despite treatment advances over the past decades, schizophrenia remains one of the most severe psychiatric disorders that is associated with a chronic relapsing course and marked functional impairment in a substantial proportion of patients. In this article, a historical overview of the pharmacologic advances in the treatment of schizophrenia over the past 50 years is presented. This is followed by a review of the current developments in optimizing the treatment and outcomes in patients with schizophrenia. Methodological challenges, potential solutions, and areas of particular need for further research are highlighted. Although treatment goals of response, remission, and recovery have been defined more uniformly, a good "effectiveness" measure mapping onto functional outcomes is still lacking. Moreover, the field must advance in transferring measurement-based approaches from research to clinical practice. There is an ongoing debate regarding whether and which first- or second-generation antipsychotics should be used. However, especially when considering individual adverse effect profiles, the differentiation into first- and second-generation antipsychotics as unified classes cannot be upheld, and a more differentiated view and treatment selection are required. The desired, individualized treatment approach needs to consider current symptoms, comorbid conditions, past therapeutic response, and adverse effects, as well as patient choice and expectations. Acute and long-term goals and effects of medication treatment should be balanced. To date, clozapine is the only evidence-based treatment for refractory patients, and the role of antipsychotic polypharmacy and other augmentation strategies remains unclear, at best. To discover novel treatments with enhanced/broader efficacy and improved tolerability, and to enable personalized treatment, the mechanisms underlying illness development and progression, symptomatic improvement, and side effect development need to be elucidated.
Collapse
Affiliation(s)
- John M Kane
- Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, NY 11004, USA.
| | | |
Collapse
|
9
|
Leucht S, Shamsi SAR, Busch R, Kissling W, Kane JM. Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study. Schizophr Res 2008; 101:312-9. [PMID: 18308513 DOI: 10.1016/j.schres.2008.01.018] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2007] [Revised: 01/10/2008] [Accepted: 01/18/2008] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To use the degree of response after 2 weeks of treatment to predict non-response at 4 to 6 weeks. METHOD Post-hoc re-analysis of a large multi-centered double-blind trial including 1996 patients with schizophrenia using receiver-operator curves and logistic regression analyses to predict non-response at 4 weeks and at 4-6 weeks from the percentage BPRS change at weeks 1 and 2. The primary non-response criterion was a less than 25% BPRS reduction from baseline. RESULTS A 0% BPRS reduction at 2 weeks predicted non-response at 4 weeks with a positive predictive value of 77.1%; and sustained non-response at weeks 4, 5 and 6 with a positive predictive value of 75.8%. In a secondary last-observation-carried forward-analysis a less stringent cutoff of < or =15% BPRS reduction was associated with an acceptable positive predictive value (75%), with even higher sensitivity (76%). CONCLUSIONS Those patients who showed little to no reduction of symptoms at week 2 were unlikely to show even minimal response at weeks 4 to 6. There is increasing evidence that such patients may benefit from a change in treatment.
Collapse
Affiliation(s)
- Stefan Leucht
- Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universität München, Ismaningerstr. 22, 81675 München, Germany.
| | | | | | | | | |
Collapse
|
10
|
Abstract
OBJECTIVE Researchers, by studying first-generation antipsychotics, have established an early prediction model, which had a favorable specificity but a low sensitivity. This study aims to optimize early prediction of treatment response for schizophrenia using a novel statistic method that can be done even under the Microsoft Excel system of a personal computer. METHODS One hundred twenty-three inpatients with acutely exacerbated schizophrenia were given optimal therapy of risperidone, a commonly used second-generation antipsychotic agent. Response was defined as a reduction of 20% or more in the Positive and Negative Syndrome Scale total score. We applied the generalized estimating equation method's logistic regression to establish an early prediction model based on the treatment results of the first and the second weeks. RESULTS The proposed method correctly predicted nonresponse at 4 and 6 weeks in 80.8% and 81.8% of the patients, respectively. The method also identified responder at 4 and 6 weeks in 80.0% and 82.8%, respectively. The predictive powers (or correct prediction rates) at 4 and 6 weeks were 80.3% and 82.4%, respectively. In addition, the results based on the responses in Positive and Negative Syndrome Scale scores were slightly better than those in Brief Psychiatric Rating Scale scores. CONCLUSIONS Using the first 2 weeks' treatment results to predict the fourth or sixth week's treatment response is acceptable in terms of specificity, sensitivity, and predictive power. Further studies are needed. Moreover, whether this model could be applied to establish a prediction system for other psychotropics, such as antidepressants, also deserves research.
Collapse
Affiliation(s)
- Yue-Cune Chang
- Institute of Life Science and Department of Mathematics, Tamkang University, Tamsui, Taipei, Taiwan.
| | | | | | | |
Collapse
|
11
|
Lane HY, Chang YC, Chiu CC, Chen TT, Lee SH, Chang WH. Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics. J Clin Psychopharmacol 2002; 22:353-8. [PMID: 12172333 DOI: 10.1097/00004714-200208000-00004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Response predictors of risperidone or other newer atypical antipsychotics for schizophrenia treatment remain unclear. This study aimed to investigate the influence of patient demographics on risperidone efficacy for schizophrenia. One hundred twenty-one newly hospitalized patients who had schizophrenia with acute exacerbation entered this prospective, 6-week risperidone trial. The target dose was 6 mg/day, or lower in case of side effects. Consequently, the mean +/- SD dose remained quite stable after week 2 and reached 4.4 +/- 1.3 mg/day at week 6. Efficacy and side effect assessments were conducted biweekly. The mean total score of the Positive and Negative Syndrome Scale (PANSS) declined during the trial, particularly within the first 4 weeks. Further, of the various efficacy scores (and their natural logarithm values) collected, only the logarithm of the PANSS total score was selected to serve as the response value, because it was normally distributed and thus suitable for regression analyses. After adjusting the effects of treatment duration (weeks 0-6) and other patient-related variables with the generalized estimating equation method, each 1-week increase in duration of prior hospitalizations raised the PANSS total by 0.04% (p = 0.002) and each 1-year increment in the education duration decreased the PANSS by 0.94% (p = 0.04). Gender, age, age at illness onset, duration of illness, diagnosis subtype, or number of prior hospitalizations, however, did not significantly impact the response value. These preliminary results suggest that longer hospitalization duration and shorter education predict higher symptomatology. Further studies with longer observation and larger samples in not only acutely ill patients but also other populations (e.g., first-episode patients) are warranted.
Collapse
Affiliation(s)
- Hsien-Yuan Lane
- Department of Psychiatry, Tzu-Chi General Hospital and Tzu-Chi University, Taichung, Taiwan
| | | | | | | | | | | |
Collapse
|
12
|
Miller R. Dose-response relationships for the antipsychotic effects and Parkinsonian side-effects of typical neuroleptic drugs: practical and theoretical implications. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21:1059-94. [PMID: 9421824 DOI: 10.1016/s0278-5846(97)00099-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
1. From a review of published literature it is concluded that the minimum dose of a neuroleptic drug (NLD) required to alleviate psychosis is very similar to that producing minimal parkinsonian side effects (PSE). This conclusion is reached both from group comparisons and individual comparisons of dose/response relations (DRR) for the two effects. 2. A lower dose of NLD is usually sufficient to prevent relapse in well stabilized patients than is needed to check an active psychotic state. 3. Anticholinergic agents used to reduce side effects of typical NLD can retard the therapeutic process during neuroleptic treatment of acute psychosis. Although it is not fully established that this is a central interaction, it is consistent with the idea that minimal side effects are a necessary condition for therapeutic effectiveness with typical antipsychotic drugs. 4. In relapse-free maintenance of psychosis-prone patients, tolerance occurs to PSE. Thus few patients need experience prolonged side effects during maintenance treatment with neuroleptics. 5. The evidence reviewed is discussed with respect to a previous hypothesis of the supposedly "indirect" action of typical neuroleptic drugs in therapy for psychosis. The evidence is consistent with the idea of a close causal relation between minimal PSE of these drugs, and their therapeutic effectiveness in the acute stage of treatment.
Collapse
Affiliation(s)
- R Miller
- Department of Anatomy and Structural Biology, University of Otago Medical School, Dunedin, New Zealand
| |
Collapse
|
13
|
Seeman MV. Schizophrenia, gender, and affect. CANADIAN JOURNAL OF PSYCHIATRY. REVUE CANADIENNE DE PSYCHIATRIE 1996; 41:263-4. [PMID: 8793143 DOI: 10.1177/070674379604100501] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
14
|
Glick M, Mazure CM, Bowers MB, Zigler E. Premorbid social competence and the effectiveness of early neuroleptic treatment. Compr Psychiatry 1993; 34:396-401. [PMID: 7907536 DOI: 10.1016/0010-440x(93)90064-b] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
The relationship of premorbid social competence to early psychotic symptom resolution was examined in 84 (44 male, 40 female) acutely psychotic inpatients given fixed-dose neuroleptic treatment. Patients with a substantial reduction in psychotic symptomatology at 10 days had higher overall social competence scores and higher scores on the indices of occupation, marital status, age, and employment history than did patients with little symptom resolution. Sex and diagnosis were not related to degree of psychotic symptom resolution. The results suggest that early symptom resolution with neuroleptic treatment represents yet another instance of outcome being related to premorbid social competence. The findings likewise accord with the view that social competence reflects underlying developmental differences.
Collapse
Affiliation(s)
- M Glick
- Department of Psychology, Yale University, New Haven, CT 06520
| | | | | | | |
Collapse
|
15
|
Stern RG, Kahn RS, Harvey PD, Amin F, Apter SH, Hirschowitz J. Early response to haloperidol treatment in chronic schizophrenia. Schizophr Res 1993; 10:165-71. [PMID: 8398949 DOI: 10.1016/0920-9964(93)90052-k] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
This study examined the time-course of treatment response to haloperidol in chronic schizophrenia. Furthermore the predictive value of baseline psychopathology and early therapeutic changes for the identification of the eventual treatment outcome was examined. After a two-week drug-free period forty-three chronic schizophrenic patients were treated with haloperidol for five weeks. Psychopathology was assessed on the last drug-free day and on the third and eighth day from the initiation of treatment, and then at weekly intervals. At the end of the study based on a priori criteria patients were classified as responders or non-responders to haloperidol. Seventeen patients met criteria for treatment response at the end of five weeks of treatment, while 26 did not. Already by the third day of treatment, in the responders there was a significant decrease in total BPRS and in the subscales scores for psychosis, tension and anergia, but not for hostility-suspiciousness and depression. These decreases represented approximately half of the eventual improvement obtained by the end of the study. Discriminant function analysis showed that severity of symptoms at baseline and improvement by day 3 correctly classified overall outcome in 72% of the cases.
Collapse
Affiliation(s)
- R G Stern
- Department of Psychiatry, Bronx Veteran Administration Medical Center, Mount Sinai School of Medicine, New York, NY 10029
| | | | | | | | | | | |
Collapse
|
16
|
McDermott BE, Sautter FJ, Garver DL. Heterogeneity of schizophrenia: relationship to latency of neuroleptic response. Psychiatry Res 1991; 37:97-103. [PMID: 1862165 DOI: 10.1016/0165-1781(91)90109-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Patients with an index diagnosis of schizophrenia were compared to patients with an index diagnosis of schizophreniform disorder to determine if they differed in latency to therapeutic response to haloperidol. The results of a survival analysis showed that patients with a diagnosis of schizophreniform disorder responded to haloperidol significantly more rapidly than did patients with a diagnosis of schizophrenia. Inspection of time-to-response slopes revealed that approximately 75% of the schizophreniform patients responded to neuroleptics on or before day 8 of treatment, whereas only 20% of the schizophrenic patients responded this rapidly. Forty percent of schizophrenic patients responded between day 8 and day 18, and 30% between day 18 and day 36. These results indicate that schizophreniform disorder has been successfully separated from schizophrenia in DSM-III, at least in relationship to drug response.
Collapse
Affiliation(s)
- B E McDermott
- Department of Psychiatry and Neurology, Tulane University School of Medicine, New Orleans, LA 70112
| | | | | |
Collapse
|
17
|
Bartkó G, Frecska E, Horváth S, Zádor G, Arató M. Predicting neuroleptic response from a combination of multilevel variables in acute schizophrenic patients. Acta Psychiatr Scand 1990; 82:408-12. [PMID: 1981296 DOI: 10.1111/j.1600-0447.1990.tb03070.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
A predetermined set of 22 sociodemographic, psychosocial, clinical, neurocognitive and biochemical potential predictor variables was tested in 98 schizophrenic patients admitted for relapse. The patients were treated with neuroleptics, mostly with haloperidol, for 28 d. Ten of the 22 variables correlated significantly with the neuroleptic response. Using stepwise multiple regression analyses, an optimal combination of 5 predictors was found to be in hierarchical order: disturbances of premorbid adjustment, intensity of positive symptoms at admission, family history of schizophrenia, working ability during the year before admission and serum dopamine-beta-hydroxylase. The 5 best predictors explained 29% of outcome variance, and all 22 variables together explained 35%. Such neurological characteristics as neurological soft signs, handedness, abnormal voluntary movements, spontaneous blink rate and cognitive impairment did not predict the treatment response. Several psychopathological, psychosocial and clinical predictors known from the literature could also be confirmed by cross-validation.
Collapse
Affiliation(s)
- G Bartkó
- National Institute for Nervous and Mental Diseases, Budapest, Hungary
| | | | | | | | | |
Collapse
|
18
|
Albus M, Lecrubier Y, Maier W, Buller R, Rosenberg R, Hippius H. Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatr Scand 1990; 82:359-65. [PMID: 2281806 DOI: 10.1111/j.1600-0447.1990.tb01401.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
One of the core problems in clinical research is the detection of early changes in target symptoms that predict future therapeutic outcome. To analyze potential predictors of outcome, data of a multicenter study on patients with panic disorder were used. A total of 1010 patients were randomly allocated either to alprazolam, imipramine or placebo treatment. Early improvement in the number of spontaneous panic attacks within the first week of treatment predicted outcome exclusively in the alprazolam group. In contrast, placebo responders and nonresponders were differentiated by early changes in anticipatory anxiety intensity. For tricyclic antidepressants such as imipramine an evaluation period of more than one week is required to allow conclusions about outcome.
Collapse
Affiliation(s)
- M Albus
- Psychiatric Hospital, University of Munich, Federal Republic of Germany
| | | | | | | | | | | |
Collapse
|
19
|
Angermeyer MC, Goldstein JM, Kuehn L. Gender differences in schizophrenia: rehospitalization and community survival. Psychol Med 1989; 19:365-382. [PMID: 2762441 DOI: 10.1017/s0033291700012411] [Citation(s) in RCA: 76] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
This study tested the hypothesis that schizophrenic men experience a poorer course than schizophrenic women. A representative sample from Hannover, FRG, including 278 first admission DSM-III schizophrenics, were followed for three years. Findings demonstrated that schizophrenic women experience fewer rehospitalizations, shorter lengths of stay, and survive longer in the community than schizophrenic men. Implications of the role of gender for schizophrenia are discussed.
Collapse
Affiliation(s)
- M C Angermeyer
- Department of Psychiatric Sociology, Central Institute of Mental Health, Mannheim, FRG
| | | | | |
Collapse
|